| Trial ID: | L1809 |
| Source ID: | NCT01822548
|
| Associated Drug: |
Vildagliptin
|
| Title: |
Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01822548/results
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Vildagliptin|DRUG: Glibenclamide|DRUG: Metformin
|
| Outcome Measures: |
Primary: Absolute Change in the Endothelial Progenitor Cell (EPC) Number, The study primary endpoint was the change from baseline values of the EPC number in the Vildagliptin vs Glibenclamide arm at 4 and 12 months., V0, V2 (month 4), V4 (12 month) | Secondary: Absolute Change in HbA1C Compared to Baseline, The secondary endpoint was the change from baseline values of HbA1C in the Vildagliptin vs Glibenclamide arm at 4 and 12 months, V0 (randomization), V2 (month4), V4 (month 12).
|
| Sponsor/Collaborators: |
Sponsor: Azienda Ospedaliero-Universitaria di Parma
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
64
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2010-10
|
| Completion Date: |
2015-01
|
| Results First Posted: |
2017-08-02
|
| Last Update Posted: |
2017-08-02
|
| Locations: |
Azienda Opedaliera-Universitaria, Parma, 43126, Italy|Azienda Ospedaliera-Universitaria, Parma, 43126, Italy
|
| URL: |
https://clinicaltrials.gov/show/NCT01822548
|
